中國天弓控股(00428.HK)擬折讓約6.08%配售最多1785萬股
格隆匯5月26日丨中國天弓控股(00428.HK)公告,於2025年5月26日,公司與配售代理訂立配售協議,據此,公司已經委任配售代理,按盡力基準促成承配人認購最多1785萬股配售股份,相當於本公佈日期現有已發行股本約20.00%;及經配發及發行配售股份擴大後已發行股本約16.67%。每股配售股份配售價0.170港元,配售價較5月26日在聯交所所報收市價每股0.181港元折讓約6.08%。
配售事項所得款項淨額將約爲2.9百萬港元。配售事項所得款項淨額中擬用作投資於上市及╱或非上市證券爲數合共約2.5百萬港元,而餘額則將會用作集團的一般營運資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.